GlobeNewsWire
23 Sept 2026, 21:41 UTC · 1h ago
Verdict
Headline takes no side. We score CSR −0.60 across four claims — strongly bearish.
−0.60strongly bearish
More negative than 79% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
Brodsky & Smith is investigating whether the Personalis Board breached fiduciary duties regarding its acquisition by Tempus AI for $16.25 per share.
Newpress release dated Sept. 23, 2026
So whatLegal challenges to the $1.5 billion enterprise value deal could delay the closing timeline or force a price renegotiation.
More negative than 79% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Brodsky & Smith is investigating if the Weave Communications Board failed to secure fair value in its $7.40 per share cash acquisition by Francisco Partners.
Newpress release dated Sept. 23, 2026
So whatLitigation over the $650 million aggregate equity valuation often leads to short-term volatility in the arbitrage spread.
More negative than 79% of claims this week
The acquisition of Centerspace by Independence Realty Trust involves an all-stock exchange of 3.800 IRT shares for each CSR share, which is currently under investigation for fair value.
Newpress release dated Sept. 23, 2026
So whatSince CSR shareholders will only own 22% of the combined equity, a successful claim could shift the exchange ratio.
More negative than 71% of claims this week
Brodsky & Smith is investigating the acquisition of Fulcrum Therapeutics by Slate Medicines, where Fulcrum stockholders are expected to own 5.0% of the combined company.
Newpress release dated Sept. 23, 2026
So whatThe extreme asymmetry in ownership (95% for Slate) makes the 'fair value' claim a primary risk for FULC shareholders before the merger closes.
More negative than 71% of claims this week
Which stocks this story touches
More negative than 79% of ticker scores this week
The company is the subject of a legal investigation into whether its Board breached fiduciary duties regarding a merger.
More negative than 79% of ticker scores this week
The company is under investigation for potential breaches of fiduciary duty regarding its acquisition by Slate Medicines.
More negative than 79% of ticker scores this week
The company's Board is being investigated for potential breaches of fiduciary duty related to its merger with Tempus AI.
More negative than 79% of ticker scores this week
The company is under investigation to determine if shareholders are receiving fair value in its acquisition by Francisco Partners.
More negative than 67% of ticker scores this week
The company is acquiring CSR, which is currently facing legal scrutiny over the fairness of the transaction.
More negative than 67% of ticker scores this week
The company is acquiring PSNL, a transaction that is currently being investigated for fairness to shareholders.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
More positive than 95% of relationship scores this week
[a_to_b] Tempus AI, Inc. (TEM) is acquiring Personalis, Inc. (PSNL) for $16.25 per share.
—
CSR hasn't traded since this ran. Last close $55.08 (Sep 23); the reaction starts at the next open.
CSR chart →
